SG11202001182QA - Macrocyclic mcl-1 inhibitors and methods of use - Google Patents

Macrocyclic mcl-1 inhibitors and methods of use

Info

Publication number: SG11202001182QA
Authority: SG; Singapore
Prior art keywords: inhibitors; methods; mcl; macrocyclic; macrocyclic mcl
Prior art date: 2017-08-15

Application number

SG11202001182QA

Inventor

Wilfried Braje

George Doherty

Katja Jantos

Cheng Ji

Andrew Judd

Aaron Kunzer

Anthony Mastracchio

Xiaohong Song

Andrew Souers

Gerard Sullivan

Zhi-Fu Tao

Jesse Teske

Xilu Wang

Michael Wendt

Thomas Penning

Chunqui Lai

Andreas Kling

Frauke Pohlki

Original Assignee

Abbvie Inc

Abbvie Deutschland

Wilfried Braje

George Doherty

Katja Jantos

Cheng Ji

Andrew Judd

Aaron Kunzer

Anthony Mastracchio

Xiaohong Song

Andrew Souers

Gerard Sullivan

Tao Zhi Fu

Jesse Teske

Xilu Wang

Michael Wendt

Thomas Penning

Chunqui Lai

Andreas Kling

Frauke Pohlki

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-08-15

Filing date

2018-08-15

Publication date

2020-03-30

2018-08-15 Application filed by Abbvie Inc, Abbvie Deutschland, Wilfried Braje, George Doherty, Katja Jantos, Cheng Ji, Andrew Judd, Aaron Kunzer, Anthony Mastracchio, Xiaohong Song, Andrew Souers, Gerard Sullivan, Tao Zhi Fu, Jesse Teske, Xilu Wang, Michael Wendt, Thomas Penning, Chunqui Lai, Andreas Kling, Frauke Pohlki filed Critical Abbvie Inc

2020-03-30 Publication of SG11202001182QA publication Critical patent/SG11202001182QA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

SG11202001182QA 2017-08-15 2018-08-15 Macrocyclic mcl-1 inhibitors and methods of use SG11202001182QA (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201762545853P	2017-08-15	2017-08-15
US201762555475P	2017-09-07	2017-09-07
US201862692663P	2018-06-30	2018-06-30
PCT/US2018/000180 WO2019035911A1 (en)	2017-08-15	2018-08-15	Macrocyclic mcl-1 inhibitors and methods of use

Publications (1)

Publication Number	Publication Date
SG11202001182QA true SG11202001182QA (en)	2020-03-30

Family

ID=65362347

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11202001182QA SG11202001182QA (en)	2017-08-15	2018-08-15	Macrocyclic mcl-1 inhibitors and methods of use
SG10202106345VA SG10202106345VA (en)	2017-08-15	2018-08-15	Macrocyclic mcl-1 inhibitors and methods of use

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10202106345VA SG10202106345VA (en)	2017-08-15	2018-08-15	Macrocyclic mcl-1 inhibitors and methods of use

Country Status (22)

Country	Link
US (4)	US10676485B2 (en)
EP (2)	EP3988555A1 (en)
JP (1)	JP2020531433A (en)
KR (1)	KR20200041942A (en)
CN (1)	CN111818917A (en)
AU (1)	AU2018316620A1 (en)
BR (1)	BR112020003180A2 (en)
CA (1)	CA3073112A1 (en)
CL (2)	CL2020000363A1 (en)
CO (1)	CO2020002678A2 (en)
CR (1)	CR20200124A (en)
EC (1)	ECSP20018703A (en)
IL (1)	IL272681A (en)
MX (1)	MX2020001717A (en)
PE (1)	PE20200837A1 (en)
PH (1)	PH12020500327A1 (en)
RU (1)	RU2020110517A (en)
SG (2)	SG11202001182QA (en)
TW (1)	TW201920194A (en)
UA (1)	UA126586C2 (en)
UY (1)	UY37843A (en)
WO (1)	WO2019035911A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3073114A1 (en) *	2017-08-15	2019-02-21	Abbvie Inc.	Macrocyclic mcl-1 inhibitors and methods of use
CR20200124A (en) *	2017-08-15	2020-09-28	Abbvie Inc	Macrocyclic mcl-1 inhibitors and methods of use
EP3668504A4 (en) *	2017-08-15	2021-05-05	AbbVie Inc.	Macrocyclic mcl-1 inhibitors and methods of use
ES2966825T3 (en)	2017-08-15	2024-04-24	Agios Pharmaceuticals Inc	Pyruvate kinase activators for use in the treatment of blood disorders
BR112020003494A2 (en)	2017-09-07	2020-08-25	Augusta University Research Institute, Inc	compound, methods to increase an immunosuppressive response, to treat an inflammatory disorder, an autoimmune disease, graft versus host disease, chronic infection and obesity and to inhibit or reduce rejection to a transplant, and pharmaceutical composition
CN109467538A (en)	2017-09-07	2019-03-15	和记黄埔医药（上海）有限公司	Cycloalkene-substituted heteroaromatic compounds and their uses
US20230081720A1 (en)	2019-05-20	2023-03-16	Novartis Ag	Mcl-1 inhibitor antibody-drug conjugates and methods of use
CA3202759A1 (en)	2020-11-24	2022-06-02	Novartis Ag	Mcl-1 inhibitor antibody-drug conjugates and methods of use
JP2024520801A (en)	2021-06-11	2024-05-24	ギリアードサイエンシーズ，インコーポレイテッド	Combination of MCL-1 inhibitor and anticancer drug
CA3222752A1 (en)	2021-06-11	2022-12-15	Gilead Sciences, Inc.	Combination mcl-1 inhibitors with anti-body drug conjugates
PE20251072A1 (en)	2022-05-20	2025-04-10	Novartis Ag	Antibody-drug conjugates of antineoplastic compounds and methods of using them
WO2025111431A1 (en)	2023-11-22	2025-05-30	Les Laboratoires Servier	Anti-cd7 antibody-drug conjugates and methods of use thereof
TW202540185A (en)	2023-11-22	2025-10-16	法商施維雅藥廠	Anti-cd74 antibody-drug conjugates and methods of use thereof
TW202530255A (en)	2023-12-15	2025-08-01	法商亞維西亞有限公司	Anti il-1rap binding domains and antibody-drug conjugates thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2616255T3 (en) *	2008-04-30	2017-06-12	National Health Research Institutes	Condensed bicyclic pyrimidine compounds as aurora kinase inhibitors
FR3015483B1 (en)	2013-12-23	2016-01-01	Servier Lab	NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
JO3474B1 (en) *	2014-08-29	2020-07-05	Amgen Inc	Tetrahydronaphthalene derivatives that inhibit mcl-1 protein
FR3037959B1 (en)	2015-06-23	2017-08-04	Servier Lab	NOVEL BICYCLIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3037957B1 (en)	2015-06-23	2019-01-25	Les Laboratoires Servier	NOVEL HYDROXYESTER DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3037958B1 (en)	2015-06-23	2019-01-25	Les Laboratoires Servier	NOVEL HYDROXY ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR3037956B1 (en)	2015-06-23	2017-08-04	Servier Lab	NOVEL AMINO ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3046792B1 (en)	2016-01-19	2018-02-02	Les Laboratoires Servier	NOVEL AMMONIUM DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HRP20200673T1 (en)	2016-04-22	2020-07-10	Astrazeneca Ab	Macrocyclic mcl1 inhibitors for treating cancer
AU2017300738A1 (en)	2016-07-22	2019-02-07	Les Laboratoires Servier	Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
IL266198B2 (en)	2016-10-28	2023-11-01	Servier Lab	Liposomal formulation for use in the treatment of cancer
EP3567043B1 (en)	2017-01-05	2023-12-06	Henan Genuine Biotech Co., Ltd.	2-[[5-[(4-hydroxy-3-chloro-2-methyl)-phenyl]-thieno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-methoxybenzene)propanoic acid derivatives as mcl-1 and bcl-2 inhibitors for treating cancer
UY37560A (en)	2017-01-06	2018-07-31	Servier Lab	COMBINATION OF AN MCL-1 INHIBITOR AND A TAXAN COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS
CA3073114A1 (en)	2017-08-15	2019-02-21	Abbvie Inc.	Macrocyclic mcl-1 inhibitors and methods of use
EP3668504A4 (en) *	2017-08-15	2021-05-05	AbbVie Inc.	Macrocyclic mcl-1 inhibitors and methods of use
CR20200124A (en) *	2017-08-15	2020-09-28	Abbvie Inc	Macrocyclic mcl-1 inhibitors and methods of use
CN107573360B (en)	2017-10-27	2019-08-09	都创(上海)医药科技有限公司	A kind of preparation method of multiple target point small molecule compound S63845

2018
- 2018-08-15 CR CR20200124A patent/CR20200124A/en unknown
- 2018-08-15 SG SG11202001182QA patent/SG11202001182QA/en unknown
- 2018-08-15 EP EP21197248.4A patent/EP3988555A1/en active Pending
- 2018-08-15 EP EP18846737.7A patent/EP3652184A1/en not_active Withdrawn
- 2018-08-15 TW TW107128523A patent/TW201920194A/en unknown
- 2018-08-15 MX MX2020001717A patent/MX2020001717A/en unknown
- 2018-08-15 PE PE2020000240A patent/PE20200837A1/en unknown
- 2018-08-15 JP JP2020508463A patent/JP2020531433A/en active Pending
- 2018-08-15 CA CA3073112A patent/CA3073112A1/en active Pending
- 2018-08-15 AU AU2018316620A patent/AU2018316620A1/en not_active Abandoned
- 2018-08-15 CN CN201880066986.9A patent/CN111818917A/en active Pending
- 2018-08-15 UA UAA202001749A patent/UA126586C2/en unknown
- 2018-08-15 RU RU2020110517A patent/RU2020110517A/en unknown
- 2018-08-15 WO PCT/US2018/000180 patent/WO2019035911A1/en not_active Ceased
- 2018-08-15 KR KR1020207007568A patent/KR20200041942A/en not_active Ceased
- 2018-08-15 UY UY0001037843A patent/UY37843A/en not_active Application Discontinuation
- 2018-08-15 US US15/998,789 patent/US10676485B2/en active Active
- 2018-08-15 BR BR112020003180-1A patent/BR112020003180A2/en not_active IP Right Cessation
- 2018-08-15 SG SG10202106345VA patent/SG10202106345VA/en unknown
2020
- 2020-02-12 CL CL2020000363A patent/CL2020000363A1/en unknown
- 2020-02-13 PH PH12020500327A patent/PH12020500327A1/en unknown
- 2020-02-14 IL IL272681A patent/IL272681A/en unknown
- 2020-03-10 CO CONC2020/0002678A patent/CO2020002678A2/en unknown
- 2020-03-13 EC ECSENADI202018703A patent/ECSP20018703A/en unknown
- 2020-05-11 US US16/872,279 patent/US20200325153A1/en not_active Abandoned
- 2020-11-12 CL CL2020002943A patent/CL2020002943A1/en unknown
2022
- 2022-02-03 US US17/649,906 patent/US20230183261A1/en not_active Abandoned
2024
- 2024-02-29 US US18/592,020 patent/US20250092062A1/en active Pending

Also Published As

Publication number	Publication date
IL272681A (en)	2020-03-31
BR112020003180A2 (en)	2020-09-15
TW201920194A (en)	2019-06-01
EP3652184A4 (en)	2020-05-20
WO2019035911A1 (en)	2019-02-21
AU2018316620A1 (en)	2020-03-12
EP3988555A1 (en)	2022-04-27
CN111818917A (en)	2020-10-23
CA3073112A1 (en)	2019-02-21
US20250092062A1 (en)	2025-03-20
CL2020000363A1 (en)	2020-06-12
UA126586C2 (en)	2022-11-02
SG10202106345VA (en)	2021-07-29
CR20200124A (en)	2020-09-28
PH12020500327A1 (en)	2020-10-12
JP2020531433A (en)	2020-11-05
RU2020110517A3 (en)	2022-03-23
US20230183261A1 (en)	2023-06-15
ECSP20018703A (en)	2020-04-22
CL2020002943A1 (en)	2021-03-12
EP3652184A1 (en)	2020-05-20
PE20200837A1 (en)	2020-08-13
KR20200041942A (en)	2020-04-22
MX2020001717A (en)	2020-10-08
US20200325153A1 (en)	2020-10-15
CO2020002678A2 (en)	2020-08-10
RU2020110517A (en)	2021-09-16
US20190144465A1 (en)	2019-05-16
US10676485B2 (en)	2020-06-09
UY37843A (en)	2019-03-29

Publication	Publication Date	Title
IL272681A (en)	2020-03-31	Macrocyclic mcl-1 inhibitors and methods of use
EP3668503A4 (en)	2021-04-07	Macrocyclic mcl-1 inhibitors and methods of use
IL261606A (en)	2018-10-31	Substituted inhibitors of menin-mll and methods of use
IL267291A (en)	2019-08-29	Ectonucleotidase inhibitors and methods of use thereof
IL271999A (en)	2020-02-27	Tyk2 inhibitors and uses thereof
ZA201905677B (en)	2022-12-21	Glycan-interacting compounds and methods of use
IL274504A (en)	2020-06-30	Acss2 inhibitors and methods of use thereof
IL261625B (en)	2021-08-31	Bridged bicyclic inhibitors of menin-mll and methods of use
IL259801A (en)	2018-07-31	Inhibitors of ezh2 and methods of use thereof
IL250496A0 (en)	2017-03-30	Expandable body device and method of use
EP3268369A4 (en)	2018-08-08	Anti-alphavbeta1 integrin inhibitors and methods of use
PL3548033T3 (en)	2025-06-02	Compounds and their methods of use
IL279475B2 (en)	2026-01-01	Ectonucleotidase inhibitors and methods of use thereof
LT3700902T (en)	2023-06-26	Inhibitors of trpc6
ZA202100643B (en)	2023-03-29	Rnai agents for inhibiting expression of alpha-enac and methods of use
GB201609786D0 (en)	2016-07-20	Compounds and method of use
LT3621694T (en)	2023-11-27	Lrrc33 inhibitors and use thereof
IL267238A (en)	2019-08-29	Heparanase inhibitors and use thereof
SG11201605915WA (en)	2016-08-30	Furo-3-carboxamide derivatives and methods of use
PL3362450T3 (en)	2021-08-23	N1- and n7-substituted sibiriline derivatives and their use as inhibitors of cellular necroptosis
IL266344A (en)	2019-06-30	Inhibitors of mtor-deptor interactions and methods of use thereof
IL267243A (en)	2019-08-29	Heparanase inhibitors and use thereof
HK40019146A (en)	2020-10-09	Macrocyclic mcl-1 inhibitors and methods of use
GB201709186D0 (en)	2017-07-26	Construction block and methods of use